Mobile

A Phase 3 Randomized, Double-Blind, Placebo-controlled study of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated CLL

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-005180-24

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the effect of the addition of idelalisib (formerly GS-1101) to rituximab on progression-free survival (PFS) in subjects with previously treated chronic lymphocytic leukemia (CLL).

Critère d'inclusion

  • Chronic lymphocytic leukemia (CLL)

Liens